Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
US11268065B2 · kind B2 · utility
0Cited by
22References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2021 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Mar 1, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.